| Document |
Document Title |
|
WO/2024/016072A1 |
The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a populat...
|
|
WO/2024/008844A1 |
The present invention relates to a process for preparing hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hept
en-1-yl]- 3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester Compound (I). I...
|
|
WO/2023/226102A1 |
Design, preparation and use of a novel macrolide, which belong to the technical field of medical intermediates. The prostaglandin macrolide intermediates A-E are obtained by means of starting from Corey lactone and 5-7 steps of conversio...
|
|
WO/2023/127855A1 |
The present disclosure provides a novel synthetic intermediate of prostaglandin or an optically active substance thereof, and a production method that uses the same. More specifically, in the method according to the present disclosure fo...
|
|
WO/2023/085135A1 |
At least one of the purposes of the present invention is to provide a novel compound. The present invention provides a compound represented by chemical formula (i). (In the formula, the bond indicated by parallel broken line and solid ...
|
|
WO/2022/167070A1 |
The present invention relates to a process for preparing hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hept
en-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-prope
n-1-yl ester of formula (I)....
|
|
WO/2022/162967A1 |
The purpose of the present invention is to provide a method for purifying tafluprost that is easy and efficient and that can also be scaled up. The present invention relates to a method for purifying tafluprost, the method including a st...
|
|
WO/2022/138586A1 |
The present invention provides a method for separating a compound represented by formula (1) or (2) (wherein P1 is a hydrogen atom or a hydroxyl-protecting group, R1 is a linear or branched, C1-6 alkyl group optionally substituted by a p...
|
|
WO/2022/057734A1 |
The present invention relates to the technical field of organic chemical engineering, and in particular to a key intermediate for synthesizing prostaglandin compounds and a preparation method therefor. When applied to the synthesis of pr...
|
|
WO/2021/091358A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically ac...
|
|
WO/2021/041320A1 |
Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
|
|
WO/2021/023693A1 |
The present invention relates to a process for preparing the hexanoic acid, 6-(nitrooxy)-,(1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino
)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenyl
ethyl)-2-propen-1-yl ester of formula (...
|
|
WO/2020/195437A1 |
The present invention provides a method for producing a compound represented by formula (1a), (1b) or (1c), the method including a step in which a compound represented by formula (3) is reduced to obtain a compound represented by formula...
|
|
WO/2020/182077A1 |
A prostaglandin as represented by formula I and an analog thereof used as medicines, and a pharmaceutical composition containing the compounds, particularly used as an inhibitor of zinc finger domain-containing protein GLI2 (i.e., glioma...
|
|
WO/2019/221641A1 |
The invention relates to medical chemistry, specifically to new biologically active compounds - amide derivatives of prostaglandin F2 alpha. Said compounds have low cytotoxicity and are able to stimulate the formation of endogenous nitri...
|
|
WO/2019/162149A1 |
The present invention relates to a process for preparing the hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hept
en-1-yl]- 3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester of formula ...
|
|
WO/2019/087948A1 |
The present invention relates to: a novel method for producing a novel prostaglandin derivative that is useful as a medicine or a pharmaceutically acceptable salt thereof; and an intermediate for the method. According to the present inve...
|
|
WO/2019/046556A1 |
Provided is a method of activating immune cells and/or an immune system response in a subject. The method may comprise administering to a subject an effective amount of a compound of Formula (I): or a prodrug, derivative, and/or salt the...
|
|
WO/2019/026402A1 |
[Problem] To provide a method for introducing substituents into an α,β-unsaturated ketone and a prostaglandin compound synthesis method utilizing said method, the former method being for introducing substituents into the α-position an...
|
|
WO/2018/220888A1 |
The present invention provides an industrially desirable novel cyclopentenone derivative, and a production method therefor. The novel compounds (the compounds represented by formula (II) and stereoisomers thereof) provided by the inventi...
|
|
WO/2018/102921A1 |
Herein presented are gold nanoparticles (AuNPs) used for the transport of medications to mucous membranes. The AuNPs are ultra-stable in that they withstand freeze-drying and heating treatments without noticeable change in their structur...
|
|
WO/2018/056905A1 |
The present invention relates to co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin. Also provided are methods of identifying or designing Nurr1-modulating l...
|
|
WO/2017/195762A1 |
The present invention relates to: a novel prostaglandin derivative having an alkynyl group in a ω-chain, particularly a novel prostaglandin derivative having a double bond at position-2 and also having an alkynyl group in a ω-chain; an...
|
|
WO/2017/182465A1 |
It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimat...
|
|
WO/2017/093770A1 |
The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Gri...
|
|
WO/2017/093771A1 |
The subject of the invention is a process for the preparation of Latanoprostene bunod of formula (I) with a purity higher than 95% where chromatography is used applying normal phase gravity silicagel column chromatography where the used ...
|
|
WO/2016/155906A1 |
The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives of fluprostenol.
|
|
WO/2016/156104A1 |
The present invention relates to 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives...
|
|
WO/2016/090461A1 |
The present invention relates to crystalline 1-adamantanamine salts, and polymorphic forms thereof, of prostaglandin analog intermediates of formula 3a, 4a and 6a, useful in the preparation of Tafluprost and Lubiprostone and processes fo...
|
|
WO/2015/187847A1 |
Disclosed are methods and compositions for treating a patient having chronic myelogenous/myeloid leukemia (CML). The methods utilize and the compositions include prostaglandin El (PGE1) or Misoprotol.
|
|
WO/2015/175984A1 |
Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.
|
|
WO/2015/136317A1 |
The subject of the invention is a process for the preparation of high purity prostaglandin acid of the general formula II wherein the bonds marked with dotted lines represent single or double bonds wherein the double bonds may be cis- or...
|
|
WO/2014/106204A1 |
The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopen
tyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as "tromethamine salt of ...
|
|
WO/2014/083367A1 |
The subject of the invention is process the preparation of travoprost of formula (I) characterized by that the free acid of formula (II) is a. ) activated with 2-chloro-l,3-dimethylimidazolinium chloride (DMC) and the resulting activated...
|
|
WO/2014/040457A1 |
An intermediate of formula (V) used for preparing limaprost of formula (I), preparation method thereof, and preparation method of limaprost therefrom. The present preparation method of limaprost from the intermediate of formula (V) inclu...
|
|
WO/2014/023256A1 |
A method for synthesis of tafluprost and intermediates thereof are provided. The method involves hydroxyl-protecting reaction using a boronate ester, boronic acid or aminoborane as a reagent, carbonyl-oxidizing reaction, and hydroxyl-dep...
|
|
WO/2012/164324A9 |
The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, - where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at po...
|
|
WO/2013/164729A1 |
Provided herein is an improved, commercially viable and industrially advantageous process for the preparation of a prostaglandin derivatives and intermediates thereof, in high yield and purity.
|
|
WO/2013/133730A1 |
A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon....
|
|
WO/2013/118058A1 |
The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the prepa...
|
|
WO/2013/104317A1 |
Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the followi...
|
|
WO/2013/093528A1 |
The invention relates to a process for the preparation of travoprost of formula(I), comprising that, the compound of formula (II), is stereoselectively reduced, the resulting compound of formula (III), is if desired crystallized, the lac...
|
|
WO/2013/040068A2 |
The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in...
|
|
WO/2013/021935A1 |
The present invention provides a compound which can be injected into a joint cavity which is an affected part of cartilage disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained ma...
|
|
WO/2012/146085A1 |
Disclosed is an intermediate (structural formula I) for synthesizing prostaglandin medicines and preparation method therefor. The intermediate is used for synthesizing prostaglandin medicines, such as bimatoprost, travoprost, latanoprost...
|
|
WO/2012/139164A1 |
The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a metho...
|
|
WO/2012/112451A1 |
Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
|
|
WO/2011/120474A9 |
The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate f...
|
|
WO/2012/011128A1 |
A process for preparing the prostaglandin derivatives is provided, wherein the benzoyl and p-nitrobenzoyl groups are used as the hydroxyl protective groups. A pharmaceutical composition comprising the prostaglandin derivatives is also pr...
|
|
WO/2012/010089A1 |
Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has in the X-ray diffraction pattern at angle 2θ the following characteristic peaks: 6.6±0.2, 9.9±0.2, 18.5±0.2°, and 20.1±0.2°. Furtherm...
|
